Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
Sponsor: Intra-Cellular Therapies, Inc.
Summary
Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.
Official title: An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to Less Than 13 Years, Diagnosed With Autism Spectrum Disorder
Key Details
Gender
All
Age Range
5 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2024-05-10
Completion Date
2026-07-31
Last Updated
2024-08-16
Healthy Volunteers
No
Conditions
Interventions
Lumateperone 10.5 mg capsule
Lumateperone 10.5 mg capsule, oral administration
Lumateperone 21 mg capsule
Lumateperone 21 mg capsule, oral administration
Lumateperone 5 mg ODT
Lumateperone 5 mg ODT, oral administration
Lumateperone 10.5 mg ODT
Lumateperone 10.5 mg ODT, oral administration
Lumateperone 15.5 mg ODT
Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
Lumateperone 21 mg ODT
Lumateperone 21 mg ODT, oral administration
Locations (8)
Clinical Site 6
Miami, Florida, United States
Clinical Site 7
Orlando, Florida, United States
Clinical Site 1
Atlanta, Georgia, United States
Clinical Site 2
Decatur, Georgia, United States
Clinical Site 3
Savannah, Georgia, United States
Clinical Site 4
Saint Charles, Missouri, United States
Clinical Site 5
Lincoln, Nebraska, United States
Clinical Site 8
Everett, Washington, United States